Iradimed Raises Low End Of Profit Outlook, Cuts Top Of Revenue Range, As Q3 Sales Hit $24.2 Million

The MRI-pump maker's third-quarter revenue rose 14% from a year earlier, while its 2026 revenue range now tops out at $93.1 million.

Share
Iradimed Raises Low End Of Profit Outlook, Cuts Top Of Revenue Range, As Q3 Sales Hit $24.2 Million

Iradimed, which makes IV pumps and patient monitors built to work safely inside MRI scanners, reported third-quarter revenue of $24.2 million, up 14% from a year earlier, and cut the top of its 2026 revenue and earnings ranges. Net income rose 17% to $6.5 million, the company said Friday.

Quarter driven by the new 3870 pump

Revenue also climbed 18% from the second quarter. Diluted earnings per share were $0.51, against $0.43 a year earlier, and adjusted earnings per share, which exclude stock-based pay, were $0.55 against $0.47.

CEO Roger Susi called it record revenue and credited the continued launch of the new 3870 MR IV pump. "Quarterly bookings also set new records," he said, with domestic pump channels booked up 45% from a year earlier.

Over 70% of pump bookings were for a "quad stack" of four pumps on one IV pole, which Susi said doubles the pump channels previously available at each MRI as customers replace the older model.

Pump revenue was $8.7 million against $8.3 million a year earlier, while vital signs monitors brought in $8.0 million, up from $6.9 million. Disposables rose to $5.0 million from $4.1 million.

The gross margin was 76%, down from 78% a year earlier. Susi said it improved from the prior quarter as manufacturing gained experience while ramping production. Operating cash flow was $7.0 million, flat with a year earlier.

A narrower full-year range

For 2026, Iradimed now expects revenue of $91.6 million to $93.1 million, from $91.0 million to $96.0 million. Adjusted earnings per share guidance is $2.07 to $2.11, from $2.06 to $2.21, and standard diluted EPS guidance is $1.90 to $1.94, from $1.90 to $2.05.

So the low end of revenue and adjusted EPS rose slightly, the low end of standard EPS held, and every top end fell.

For the fourth quarter, the company expects revenue of $25.0 million to $26.5 million and adjusted EPS of $0.57 to $0.61. Susi said that would reach a $100.0 million revenue run rate.

Cash, dividend and the business

Iradimed sells its MRidium infusion pumps and monitors mainly to hospitals. Fiscal 2025 revenue was $83.8 million. For the first nine months of 2026, revenue was $66.6 million, up 9%, and net income was $17.5 million.

Cash stood at $63.3 million on September 30, up from $51.2 million at the end of 2025. The board declared a $0.20 per-share dividend, payable November 27 to holders of record on November 13.

The fourth-quarter guidance range of $25.0 million to $26.5 million is the next test of the 3870 ramp.

Sources